Novel Self-micro Emulsifying Drug Delivery System for Safe Intramuscular Delivery with Improved Pharmacodynamics and Pharmacokinetics

Abstract

Background: Diclofenac sodium (DS) injection is widely used in the management of acute or chronic pain and inflammatory diseases. It incorporates 20 % w/v Transcutol-P as a solubilizer to make the stable injectable formulation. However, the use of Transcutol-P in high concentration leads to adverse effects such as severe nephrotoxicity, etc. Some advancements resulted in the formulation of an aqueous based injectable but that too used benzyl alcohol reported to be toxic for human use. Objective: To develop an injectable self-micro emulsifying drug delivery system (SMEDDS) as a novel carrier of DS for prompt release with better safety and efficacy. Methods: A solubility study was performed with different surfactants and co-surfactants. The conventional stirring method was employed for the formulation of SMEDDS. Detailed in vitro characterization was done for different quality control parameters. In vivo studies were performed using Wistar rats for pharmacokinetic evaluation, toxicological analysis, and analgesic activity. Results: The optimized formulation exhibited good physical stability, ideal globule size (156±0.4 nm), quick release, better therapeutics, and safety, increase in LD50 (221.9 mg/kg) to that of the commercial counterpart (109.9 mg/kg). Further, pre-treatment with optimized formulation reduced the carrageenan-induced rat paw oedema by 88±1.2 % after 4 h, compared to 77±1.6 % inhibition with commercial DS formulation. Moreover, optimized formulation significantly (p<0.05) inhibited the pain sensation in the acetic-acid induced writhing test in mice compared to its commercial equivalent with a better pharmacokinetic profile. Conclusion: The above findings confirmed that liquid SMEDDS could be a successful carrier for the safe and effective delivery of DS

Alpinetin: A Review of Its Pharmacology and Pharmacokinetics

“…Recently, the rapid nanoscience development has harvested affluent admiration in the pharmaceutical industry. Novel nanotechnologies mainly included nanoparticles, nanogel, nanocrystals, nanoemulsion, nanosuspension, micelles, liposome, solid lipid nanoparticles, self-nanoemulsifying drug delivery systems (SNEDDS), and self-micro-emulsifying drug delivery system (SMDDS) (Ahmad et al, 2016;Alothaid et al, 2021;Jain et al, 2021). Utilizing nanotechnology has created foremost progresses toward enhancing stability, bioavailability, delivery, sustained release, and therapeutic index of flavonoids (Ayala-Fuentes and Chavez-Santoscoy, 2021; Jannat et al, 2021).…”

Comparison between Ethylcellulose and Polymethacrylate Topical Nanosponges Loaded with Butenafi ne Hydrochloride

“…In addition, NS structures have enhanced thermal, physical, and chemical stability. [6][7][8][9] Butenafine hydrochloride is a benzylamine derivative, [1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl) methanamine; hydrochloride] as shown in Figure 1, with a molecular weight of 353.9 and is practically insoluble in water drug with log P~5.85. It is the first representative of a new class of antifungal agents.…”